Skip to main content

Advertisement

SpringerLink
Log in

Cancer prognostics: Past, present and p27

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Reduced expression of the p27 cell cycle inhibitor predicts poor cancer patient survival (pages 222–234).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Catzavelos, C. et al. Decreased levels of the cell cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nature Med. 3, 227–230 (1997).

    Article  CAS  Google Scholar 

  2. Porter, P. et al. Expression of cell cycle regulators p27 Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222–226 (1997).

    Article  CAS  Google Scholar 

  3. Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3, 231–234 (1997).

    Article  CAS  Google Scholar 

  4. Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1 Cell 85, 721–732 (1996).

    Article  CAS  Google Scholar 

  5. Nakayama, K. et al. Mice lacking p27 Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 85, 707–720 (1996).

    Article  CAS  Google Scholar 

  6. Hengst, L. & Reed, S. Translational control of p27 Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996).

    Article  CAS  Google Scholar 

  7. Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682–685 (1995).

    Article  CAS  Google Scholar 

  8. Muss, H. et al. c-erb-B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl. J. Med. 330, 1260–1266 (1994).

    Article  CAS  Google Scholar 

  9. Thor, A. et al. Selecting patients for higher dose adjuvant CAF: c-erb-B-2, p53 (CALGB 8869 and 8541). Proc. American Society of Clinical Oncology (in the press).

  10. Emmert-Buck, M. et al. Laser capture microdissection. Science 274, 998–1001 (1996).

    Article  CAS  Google Scholar 

  11. To affinity … and beyond! Nature Genet 14, 367–370 (1996).

Download references

Author information

Authors and Affiliations

  1. Women's Cancers Section Division of Clinical Sciences,

    Patricia S. Steeg

  2. Clinical Investigations Branch National Cancer Institute, Bethesda, Maryland, 20892, USA

    Jeffrey S. Abrams

Authors
  1. Patricia S. Steeg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey S. Abrams
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steeg, P., Abrams, J. Cancer prognostics: Past, present and p27. Nat Med 3, 152–154 (1997). https://doi.org/10.1038/nm0297-152

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0297-152

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation